Comparative Evaluation of the <i>In Vitro</i> Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>

Elias M. Mullane, Lindsay M. Avery, David P. Nicolau

Antimicrobial Agents and Chemotherapy · 2019 · 17 citations · 9 references

DOIFull text

Open access

Concepts

Abstract

(CRP) strains using gradient diffusion strips. The combinations included nonsusceptible β-lactams (cefepime, ceftolozane-tazobactam, and meropenem) with amikacin and fosfomycin. WCK 5222 MICs ranged from 2 to 32 mg/liter, and 97% were ≤16 mg/liter, while 105/146 (72%) combinations demonstrated inhibition below established susceptibility breakpoints. WCK 5222 monotherapy may be preferred over the combinations assessed for CRP infections.

References

9